Clinical trial
The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for…
NCT00041704 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00041704 |
|---|---|
| Title | The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC) |
| Official title | A Phase 2 Open-Label Study of the Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis. |
| Lead sponsor | Pfizer, Industry |
| Collaborators | Vicuron Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Candidiasis |
| Intervention type | Drug |
| Interventions | Anidulafungin, VER002 |
| Enrollment | 19 |
| Start date | Aug 1, 2002 |
| Completion | Aug 1, 2004 |
| First posted | Jul 16, 2002 |
| Last update posted | Oct 20, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: